(Q42999278)

12 November 2017

title

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy (English)

1 reference

12 November 2017

1 reference

1 reference

Wulf O Böcher

1

1 reference

12 November 2017

Marcus Schuchmann

2

1 reference

12 November 2017

Ralph Link

3

1 reference

12 November 2017

Heribert Hillenbrand

4

1 reference

12 November 2017

Fareed Rahman

5

1 reference

12 November 2017

Martin Sprinzl

6

1 reference

12 November 2017

Jonas Mudter

7

1 reference

12 November 2017

Hanns F Löhr

8

1 reference

12 November 2017

Peter R Galle

9

1 reference

12 November 2017

publication date

1 April 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

26

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

319-325

1 reference

Hepatitis C virus infection in Western Europe

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Re-treatment of chronic hepatitis C with consensus interferon .

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Principles of interferon induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01239.X

10.1111/J.1478-3231.2005.01239.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference